

- Neuroendovascular management of dural arteriovenous malformations[J]. *Neurosurg Clin N Am*, 2009, 20(4): 431–439.
- [7] van Dijk JMC, terBrugge KG, Willinsky RA, et al. Clinical course of cranial dural arteriovenous fistulas with long-term persistent cortical venous reflux[J]. *Stroke*, 2002, 33(5): 1233–1236.
- [8] Gandhi D, Chen J, Pearl M, et al. Intracranial dural arteriovenous fistulas: classification, imaging findings, and treatment[J]. *AJNR Am J Neuroradiol*, 2012, 33(6): 1007–1013.
- [9] Tsai LK, Liu HM, Jeng JS. Diagnosis and management of intracranial dural arteriovenous fistulas[J]. *Expert Rev Neurother*, 2016, 16(3): 307–318.
- [10] Yoshioka S, Moroi J, Kobayashi S, et al. A case of falcine sinus dural arteriovenous fistula[J]. *Neurosurgery*, 2013, 73(3): E554–E556.
- [11] Koyanagi M, Kobayashi T, Oda M, et al. Dural arteriovenous fistula in the falx cerebri treated with transarterial embolization using n-butyl cyanoacrylate[J]. *Surg Neurol Int*, 2016, 7(Suppl 41): S1057–S1059.
- [12] Yamaguchi T, Higaki A, Yokota H, et al. A case of dural arteriovenous fistula in the falx cerebri: case report and review of the literature[J]. *NMC Case Rep J*, 2016, 3(3): 67–70.
- [13] Tubbs RS, Loukas M, Louis RG Jr, et al. Anatomy of the falcine venous plexus[J]. *J Neurosurg*, 2007, 107(1): 155–157.
- [14] Handa J, Shimizu Y. Dural arteriovenous anomaly supplied by anterior falcine artery[J]. *Neuroradiology*, 1973, 6(4): 212–214.
- [15] Lv X, Jiang C, Li Y, et al. Results and complications of transarterial embolization of intracranial dural arteriovenous fistulas using Onyx-18[J]. *J Neurosurg*, 2008, 109(6): 1083–1090.
- [16] Yu J, Guo Y, Xu B, et al. Clinical importance of the middle meningeal artery: a review of the literature[J]. *Int J Med Sci*, 2016, 13(10): 790–799.

(本文编辑: 马萌萌, 许守超)

(上接第 5 页)

- [35] Holzer RJ, Gauvreau K, McEnaney K, et al. Long-term outcomes of the coarctation of the aorta stent trials[J]. *Circ Cardiovasc Interv*, 2021, 14(6): e010308.
- [36] Lauder L, Mahfoud F. Pacemaker-based cardiac neuromodulation therapy for the treatment of hypertension: the new kid on the block[J]. *J Am Heart Assoc*, 2021, 10(16): e022622.
- [37] Neuzil P, Merkely B, Erglis A, et al. Pacemaker-mediated programmable hypertension control therapy[J]. *J Am Heart Assoc*, 2017, 6(12): e006974.
- [38] Kalarus Z, Merkely B, Neuzil P, et al. Pacemaker-based cardiac neuromodulation therapy in patients with hypertension: a pilot study[J]. *J Am Heart Assoc*, 2021, 10(16): e020492.
- [39] Victor RG. Carotid baroreflex activation therapy for resistant hypertension[J]. *Nat Rev Cardiol*, 2015, 12(8): 451–463.
- [40] Spiering W, Williams B, Van der Heyden J, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study[J]. *Lancet*, 2017, 390(10113): 2655–2661.
- [41] Wilks SJ, Hara SA, Ross EK, et al. Non-clinical and pre-clinical testing to demonstrate safety of the barostim neo electrode for activation of carotid baroreceptors in chronic human implants[J]. *Front Neurosci*, 2017, 11: 438.
- [42] Groenland EH, Spiering W. Baroreflex amplification and carotid body modulation for the treatment of resistant hypertension[J]. *Curr Hypertens Rep*, 2020, 22(4): 27.
- [43] Bertog SC, Kolmer C, Kleschnew S, et al. Percutaneous femoral arteriovenous shunt creation for advanced chronic obstructive pulmonary disease: a single-center safety and efficacy study[J]. *Circ Cardiovasc Interv*, 2012, 5(1): 118–126.
- [44] Lobo MD, Sobotka PA, Stanton A, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial[J]. *Lancet*, 2015, 385(9978): 1634–1641.
- [45] Bialik M, Kurkowski P, Strzelecka K, et al. Dual-controlled delivery of furosemide and atenolol using a biodegradable nanosystem for antihypertensive therapy[J]. *J Drug Deliv Sci Tec*, 2023, 89: 105006.
- [46] Kouz K, Monge García MI, Cerutti E, et al. Intraoperative hypotension when using hypotension prediction index software during major noncardiac surgery: a European multicentre prospective observational registry (EU HYPROTECT)[J]. *BJA Open*, 2023, 6: 100140.

(本文编辑: 马萌萌, 许守超)